These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

170 related items for PubMed ID: 1192695

  • 21. Calcium phosphate/calcium oxalate crystal association in urinary stones: implications for heterogeneous nucleation of calcium oxalate.
    Khan SR.
    J Urol; 1997 Jan; 157(1):376-83. PubMed ID: 8976301
    [Abstract] [Full Text] [Related]

  • 22. Sequential analysis of recurrent calcium calculi by infrared spectroscopy.
    Matsuzaki S, Matsushita K, Tanikawa K, Masuda A, Matsunaga J.
    Int J Urol; 1995 Sep; 2(4):235-7. PubMed ID: 8564740
    [Abstract] [Full Text] [Related]

  • 23. Intracrystalline proteins and urolithiasis: a synchrotron X-ray diffraction study of calcium oxalate monohydrate.
    Fleming DE, Van Riessen A, Chauvet MC, Grover PK, Hunter B, van Bronswijk W, Ryall RL.
    J Bone Miner Res; 2003 Jul; 18(7):1282-91. PubMed ID: 12854839
    [Abstract] [Full Text] [Related]

  • 24. [Influence of oxianthraquinones on the crystallization of calcium oxalate and calcium phosphate: dissolution of calciumcontaining urinary calculi (author's transl)].
    Dulce HJ.
    Urologe A; 1978 Jul; 17(4):254-7. PubMed ID: 684998
    [Abstract] [Full Text] [Related]

  • 25. The effect of preincubation of seed crystals of uric acid and monosodium urate with undiluted human urine to induce precipitation of calcium oxalate in vitro : implications for urinary stone formation.
    Grover PK, Ryall RL.
    Mol Med; 2002 Sep; 8(9):525-35. PubMed ID: 12456991
    [Abstract] [Full Text] [Related]

  • 26. Nucleation of calcium oxalate crystals by albumin: involvement in the prevention of stone formation.
    Cerini C, Geider S, Dussol B, Hennequin C, Daudon M, Veesler S, Nitsche S, Boistelle R, Berthézène P, Dupuy P, Vazi A, Berland Y, Dagorn JC, Verdier JM.
    Kidney Int; 1999 May; 55(5):1776-86. PubMed ID: 10231440
    [Abstract] [Full Text] [Related]

  • 27. Saturation-inhibition index as a measure of the risk of calcium oxalate stone formation in the urinary tract.
    Robertson WG, Peacock M, Marshall RW, Marshall DH, Nordin BE.
    N Engl J Med; 1976 Jan 29; 294(5):249-52. PubMed ID: 1244550
    [Abstract] [Full Text] [Related]

  • 28. The role of trace metals in calcium urolithiasis.
    Meyer JL, Angino EE.
    Invest Urol; 1977 Mar 29; 14(5):347-50. PubMed ID: 844995
    [Abstract] [Full Text] [Related]

  • 29. Role of organic matrix in urinary stone formation: an ultrastructural study of crystal matrix interface of calcium oxalate monohydrate stones.
    Khan SR, Hackett RL.
    J Urol; 1993 Jul 29; 150(1):239-45. PubMed ID: 8510264
    [Abstract] [Full Text] [Related]

  • 30. [Mineralogical composition of urinary stones, risk factors and metabolic disturbances in patients with calcium-oxalate urolithiasis].
    Kustov AV, Strelnikov AI, Moryganov MA, Airapetyan AO, Smirnov PR, Lyalyakina EV, Toms SR.
    Urologiia; 2017 Sep 29; (4):22-26. PubMed ID: 28952687
    [Abstract] [Full Text] [Related]

  • 31. Role of agglomeration in calcium oxalate monohydrate urolith development.
    Grases F, Millan A, Söhnel O.
    Nephron; 1992 Sep 29; 61(2):145-50. PubMed ID: 1630537
    [Abstract] [Full Text] [Related]

  • 32. Quantification of crystal growth of calcium oxalate in gel and its modification by urinary constituents in a new flow model of crystallization.
    Achilles W, Freitag R, Kiss B, Riedmiller H.
    J Urol; 1995 Oct 29; 154(4):1552-6. PubMed ID: 7658589
    [Abstract] [Full Text] [Related]

  • 33. [Urinary material affecting calcium oxalate monohydrate stone formation].
    Shirane Y, Yamamoto A, Mizuta K, Hiraishi K, Kurokawa K, Kagawa S.
    Nihon Hinyokika Gakkai Zasshi; 1989 Jul 29; 80(7):995-9. PubMed ID: 2607720
    [Abstract] [Full Text] [Related]

  • 34. Crystallization during volume reduction of solutions with a composition corresponding to that in the collecting duct: the influence of hydroxyapatite seed crystals and urinary macromolecules.
    Højgaard I, Fornander AM, Nilsson MA, Tiselius HG.
    Urol Res; 1999 Dec 29; 27(6):417-25. PubMed ID: 10651129
    [Abstract] [Full Text] [Related]

  • 35. Observations on urinary stone weight correlated with composition.
    Otnes B.
    Scand J Urol Nephrol; 1983 Dec 29; 17(2):191-6. PubMed ID: 6612238
    [Abstract] [Full Text] [Related]

  • 36. Peptides of Matrix Gla protein inhibit nucleation and growth of hydroxyapatite and calcium oxalate monohydrate crystals.
    Goiko M, Dierolf J, Gleberzon JS, Liao Y, Grohe B, Goldberg HA, de Bruyn JR, Hunter GK.
    PLoS One; 2013 Dec 29; 8(11):e80344. PubMed ID: 24265810
    [Abstract] [Full Text] [Related]

  • 37. [Clinical studies on the recurrence of urolithiasis (5). Diurnal variation in urinary pH and stone compositions].
    Murayama T, Taguchi H.
    Hinyokika Kiyo; 1988 Oct 29; 34(10):1711-5. PubMed ID: 3245520
    [Abstract] [Full Text] [Related]

  • 38.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 39.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 40. An understanding of renal stone development in a mixed oxalate-phosphate system.
    Guan X, Wang L, Dosen A, Tang R, Giese RF, Giocondi JL, Orme CA, Hoyer JR, Nancollas GH.
    Langmuir; 2008 Jul 15; 24(14):7058-60. PubMed ID: 18557638
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 9.